| 4.1 Rate of exacerbations requiring systemic corticosteroids |
1 |
|
Rate Ratio (IV, Fixed, 95% CI) |
Totals not selected |
| 4.1.1 Eosinophilic |
1 |
|
Rate Ratio (IV, Fixed, 95% CI) |
Totals not selected |
| 4.2 Rate of exacerbations requiring emergency department treatment or admission |
1 |
|
Rate Ratio (IV, Fixed, 95% CI) |
Totals not selected |
| 4.2.1 Eosinophilic |
1 |
|
Rate Ratio (IV, Fixed, 95% CI) |
Totals not selected |
| 4.3 Health‐related quality of life (AQLQ mean difference) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.3.1 Eosinophilic |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.4 Health‐related quality of life (ACQ mean difference) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.4.1 Eosinophilic |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.5 Health‐related quality of life (SGRQ mean difference) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.5.1 Eosinophilic |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.6 Pre‐bronchodilator FEV 1 (litres) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.6.1 Eosinophilic |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.7 Serious adverse events |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 4.7.1 Eosinophilic |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 4.8 Adverse events leading to discontinuation |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 4.8.1 Eosinophilic |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Totals not selected |
| 4.9 Blood eosinophil level (cells × 10⁹/litre) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
| 4.9.1 Eosinophilic |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Totals not selected |
